Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter? | Zendy

Lance R. Peterson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?

Author(s) -

Lance R. Peterson

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/497594

Subject(s) - streptococcus pneumoniae , medicine , pneumonia , antibiotic resistance , antibiotics , antimicrobial , respiratory tract infections , pneumococcal infections , microbiology and biotechnology , respiratory tract , intensive care medicine , immunology , respiratory system , biology

The rate of in vitro bacterial resistance to antimicrobial agents is escalating among pathogens that cause the most serious respiratory tract infections. Many reports published during the past few years suggest that this has direct clinical implications. In particular, resistance of Streptococcus pneumoniae to beta-lactam antibiotic therapy has assumed a prominent role in the evolution of guidelines for the initial treatment of respiratory tract infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research